Transcriptomic profiling of peripheral blood mononuclear cells from rheumatoid arthritis patients before tofacitinib treatment
This study explores the molecular mechanisms underlying variable therapeutic responses to tofacitinib in patients with rheumatoid arthritis (RA). Peripheral blood mononuclear cells (PBMCs) were collected from patients with active RA before tofacitinib treatment. Based on EULAR DAS28-defined clinical outcomes after 8 weeks of therapy, patients were classified as responders or non-responders. RNA sequencing (RNA-seq) was performed to characterize transcriptomic changes associated with treatment response. The resulting dataset provides valuable insights into immune-related transcriptional alterations linked to JAK inhibitor efficacy in RA and offers a useful resource for biomarker discovery and precision medicine research.